Rxivist logo

Varying Effects of Common Tuberculosis Drugs on Enhancing Clofazimine Activity in vitro

By Shuo Zhang, Wanliang Shi, Jie Feng, Wenhong Zhang, Ying Zhang

Posted 05 Mar 2017
bioRxiv DOI: 10.1101/112573 (published DOI: 10.1038/emi.2017.24)

There is recent interest in understanding how clofazimine (CFZ) might be involved in shortening the treatment of both MDR-TB and drug-susceptible TB. The present study made a number of interesting observations that may help explain the unique ability of CFZ to shorten TB therapy, by demonstrating acid pH enhancement of CFZ activity, the varying degrees of enhancement of CFZ activity against stationary phase bacilli by different TB drugs, with PZA and RIF having the highest degree of enhancement, followed by quinolones (moxifloxacin and levofloxacin), amikacin and PAS. Future studies are needed to validate our in vitro findings in animal models of TB infection.

Download data

  • Downloaded 283 times
  • Download rankings, all-time:
    • Site-wide: 65,942 out of 109,821
    • In microbiology: 5,207 out of 9,238
  • Year to date:
    • Site-wide: 99,447 out of 109,821
  • Since beginning of last month:
    • Site-wide: 77,547 out of 109,821

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)